Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma
about
State of the science: an update on renal cell carcinomaGenetic and Chromosomal Aberrations and Their Clinical Significance in Renal NeoplasmsMolecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?Renal tumors: diagnostic and prognostic biomarkersCIViC databaseDiagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysisAnalyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis.Significance of chromosome 9p status in renal cell carcinoma: a systematic review and quality of the reported studies.Renal cell carcinoma primary cultures maintain genomic and phenotypic profile of parental tumor tissues.Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factorsChromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery.The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.CA9 overexpression is an independent favorable prognostic marker in intrahepatic cholangiocarcinoma.Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.Systemic adjuvant therapies in renal cell carcinomaPrognostic markers in renal cell carcinoma: A focus on the 'mammalian target of rapamycin' pathwayExpression of hypoxia-inducible protein 2 in renal cell carcinoma: A promising candidate for molecular targeting therapyPrognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma.Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeuticsStratification of clear cell renal cell carcinoma (ccRCC) genomes by gene-directed copy number alteration (CNA) analysisPotential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancerCarbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinomaSeeking new prognostic and predictive factors in patients with metastatic renal cell carcinoma - hypoxia-induced factors.Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer.VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy.Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinomaPrognostic markers and targeted therapies for renal cell carcinoma.Genomic heterogeneity of translocation renal cell carcinomaOpposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancerCarbonic anhydrase IX expression is associated with favorable prognostic factors in small intestinal carcinomaIn search of a better crystal ball: recent advances in prognostic markers for clear-cell renal cell carcinoma.Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma.Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.Clinical and molecular prognostic and predictive biomarkers in clear cell renal cell cancer.Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature.Next revolution in molecular theranostics: personalized medicine for urologic cancers.Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile and transcriptional landscape.Progression inference for somatic mutations in cancer.The rationale and the role of lymph node dissection in renal cell carcinoma.
P2860
Q24630685-8A058CEA-1F81-473E-A39A-ACAD31CF5B4EQ26785930-7E57D344-219C-4B95-A353-881E97DCEF73Q26825512-A968284F-F286-48B6-A227-953DAE4EC76FQ26860500-2C07C97F-F7CB-4CFF-ACEF-5EBA47A7D938Q27612411-C6577C4A-1B2C-44A9-896F-73BEB7AE25BCQ28749779-6E8FE967-1F75-4B5A-8DBE-B5FB0BA05D9EQ30671049-4A144690-0CF0-4BAB-8518-62A314A9FAFAQ33557891-2F48729A-24CC-4509-846D-1601B3DFAB85Q33616134-958DE7A1-7B01-452B-AF8F-155FF8F9E344Q33931096-665CA926-43D7-441E-BED1-5C577F73F721Q34055338-C03D4B6B-3571-4666-96D2-422E700CFED8Q34283721-C177051B-1C04-45EF-988F-F54100772765Q34365135-338D9CEE-4690-494F-8489-FC78825A1057Q35145280-C70D6735-CCFE-4007-971C-E6D007012F5DQ35451764-7AB32DD8-AD72-4ED8-8E81-DD204A061109Q35569322-5946E44A-CC87-42E8-BFE6-B39304368A4BQ35838273-0B91BFC1-85FD-40FC-A83E-B1939118B9DEQ36216688-209AFD59-4E63-499A-A3F9-1BA8F9AE0B0FQ36287965-06CD1D61-C9D7-4DBF-B926-652ADD1DD240Q36354841-644DD185-E215-456C-B14B-E13743074B01Q36367103-92510C48-B6DB-4941-A551-29D6A7A3D754Q36429759-4B5CD9D4-5C98-4BF2-941C-D9B9D1025390Q36475753-B71B9737-A931-460C-B4B7-2A3C5391ACD0Q36942552-175F68A6-92E1-4811-93D0-BD0C9325A89BQ37141969-DB2699C4-0250-4DC0-9128-6462E59B206EQ37393004-11847695-E357-4DE5-98A1-005159EA0A68Q37401553-706C6A45-7BE4-46EE-9595-9FE759C9FA26Q37414359-292D9F79-DC31-4F2E-8D2C-8A42614349B3Q37438974-CE34FF91-4D7E-4A9B-8B1E-F771DB54A61DQ37520452-4B758E54-65C6-438C-BE97-26E67CC40BD3Q37604393-0CD564BA-146A-49B1-B5CF-DBE93DD93469Q37765585-0CE5C8B7-7CEC-4101-BFAF-859C31348056Q38103580-EC5062D1-E12B-44F9-9DE3-9D601D183A81Q38196855-95137939-5814-4900-8643-9E09AA211C3CQ38294622-A56C6106-AD17-4932-8B73-ED73460F93C3Q38334611-88EB70BB-0FF5-4219-8071-1EB0C9067EFDQ38559336-3F91B883-2D7F-4711-AC1C-1A12817AC8B9Q38678106-61060454-9F42-43FB-B77E-297902C50420Q38793244-A79BA8E0-066B-4667-9430-3DD1345386D1Q38882558-45A81C95-A890-48B5-9DC8-D87818471002
P2860
Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Low CAIX expression and absenc ...... lear cell renal cell carcinoma
@ast
Low CAIX expression and absenc ...... lear cell renal cell carcinoma
@en
Low CAIX expression and absenc ...... ear cell renal cell carcinoma.
@nl
type
label
Low CAIX expression and absenc ...... lear cell renal cell carcinoma
@ast
Low CAIX expression and absenc ...... lear cell renal cell carcinoma
@en
Low CAIX expression and absenc ...... ear cell renal cell carcinoma.
@nl
altLabel
Low CAIX expression and absenc ...... lear cell renal cell carcinoma
@en
prefLabel
Low CAIX expression and absenc ...... lear cell renal cell carcinoma
@ast
Low CAIX expression and absenc ...... lear cell renal cell carcinoma
@en
Low CAIX expression and absenc ...... ear cell renal cell carcinoma.
@nl
P2093
P2860
P3181
P356
P1476
Low CAIX expression and absenc ...... lear cell renal cell carcinoma
@en
P2093
Allan J Pantuck
Arie S Belldegrun
Jonathan W Said
Patricia Fergelot
Pierre I Karakiewicz
Quoc-Dien Trinh
Tobias Klatte
P2860
P304
P3181
P356
10.1002/IJC.23496
P577
2008-07-15T00:00:00Z